Innate Pharma SA-Spons ADRIPHA
13F holders, Q4 2025 (December 31)11holders +2
5new positions
3sold out
1famous investor
$1.75avg. 13F price*
At the end of Q4 2025, 11 institutions reported holding Innate Pharma SA-Spons ADR (IPHA) in their 13F filings, up 2 from Q3 2025. 5 opened new positions and 3 sold out. The largest holders were Jane Street Group, LLC ($162K), Lion Point Capital, LP ($142K) and Morgan Stanley ($81K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Innate Pharma SA-Spons ADR
- CUSIP
- 45781K204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $390K |
| Exits | 3 | $39K |
All 13F filers, Q3 2025 → Q4 2025: 227,378 shares bought and 32,722 shares sold, net +194,656 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Jane Street Group, LLC | 0.00% | New | 92,753 | $162K |
| Lion Point Capital, LP | 0.73% | New | 81,151 | $142K |
| Morgan Stanley | 0.00% | Reduce -13.4% | 46,394 | $81K |
| Old Mission Capital LLC | 0.00% | New | 28,431 | $50K |
| Millennium Management | 0.00% | New | 20,308 | $36K |
| Rhumbline Advisers | 0.00% | Add +1007.2% | 5,204 | $9K |
| GAMMA Investing LLC | 0.00% | Reduce -53.0% | 1,073 | $2K |
| UBS Group AG | 0.00% | Reduce -80.3% | 947 | $2K |
| Farther Finance Advisors, LLC | 0.00% | No change | 10 | $18 |
| Barclays PLC | 0.00% | Reduce -99.7% | 1 | $2 |
| SageView Advisory Group, LLC | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is IPHA's weight in each manager's 13F, not the share of Innate Pharma SA-Spons ADR the manager owns.